Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 14:25
05/26/20
05/26
14:25
05/26/20
14:25
AKRO

Akero Therapeutics

$24.92 /

+0.71 (+2.93%)

, ALT

Altimmune

$8.45 /

+1.51 (+21.76%)

, ENTA

Enanta

$55.90 /

+0.78 (+1.42%)

, GLMD

Galmed

$5.51 /

-0.29 (-5.00%)

, GNFT

Genfit

$5.26 /

+0.02 (+0.38%)

, HEPA

Hepion Pharmaceuticals

$1.94 /

-0.05 (-2.51%)

, ICPT

Intercept

$77.59 /

-2.95 (-3.66%)

, MDGL

Madrigal Pharmaceuticals

$123.16 /

-2.67 (-2.12%)

, NGM

NGM Biopharmaceuticals

$21.22 /

+1.04 (+5.15%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Eric Lawitz, discuss Non-Alcoholic SteatoHepatitis (NASH) on an Analyst/Industry conference call to be held on May 26 at 3 pm.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

HEPA Hepion Pharmaceuticals
$1.94 /

-0.05 (-2.51%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

ENTA Enanta
$55.90 /

+0.78 (+1.42%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$8.45 /

+1.51 (+21.76%)

05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
ENTA Enanta
$55.90 /

+0.78 (+1.42%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$5.51 /

-0.29 (-5.00%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley FBR
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley FBR
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
GNFT Genfit
$5.26 /

+0.02 (+0.38%)

05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
05/13/20 Kepler Cheuvreux
Genfit downgraded to Reduce from Buy at Kepler Cheuvreux
05/12/20 B. Riley FBR
Genfit downgraded to Neutral from Buy at B. Riley FBR
HEPA Hepion Pharmaceuticals
$1.94 /

-0.05 (-2.51%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$77.59 /

-2.95 (-3.66%)

05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GLMD Galmed
$5.51 /

-0.29 (-5.00%)

ENTA Enanta
$55.90 /

+0.78 (+1.42%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 09:42
05/26/20
05/26
09:42
05/26/20
09:42
AKRO

Akero Therapeutics

$24.21 /

+ (+0.00%)

, ALT

Altimmune

$6.94 /

+ (+0.00%)

, ENTA

Enanta

$55.12 /

+ (+0.00%)

, GLMD

Galmed

$5.80 /

+ (+0.00%)

, GNFT

Genfit

$5.24 /

+ (+0.00%)

, HEPA

Hepion Pharmaceuticals

$1.99 /

+ (+0.00%)

, ICPT

Intercept

$80.54 /

+ (+0.00%)

, MDGL

Madrigal Pharmaceuticals

$125.83 /

+ (+0.00%)

, NGM

NGM Biopharmaceuticals

$20.18 /

+ (+0.00%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Eric Lawitz, discuss Non-Alcoholic SteatoHepatitis (NASH) on an Analyst/Industry conference call to be held on May 26 at 3 pm.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

HEPA Hepion Pharmaceuticals
$1.99 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

ENTA Enanta
$55.12 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$6.94 /

+ (+0.00%)

05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
ENTA Enanta
$55.12 /

+ (+0.00%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$5.80 /

+ (+0.00%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley FBR
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley FBR
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
GNFT Genfit
$5.24 /

+ (+0.00%)

05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
05/13/20 Kepler Cheuvreux
Genfit downgraded to Reduce from Buy at Kepler Cheuvreux
05/12/20 B. Riley FBR
Genfit downgraded to Neutral from Buy at B. Riley FBR
HEPA Hepion Pharmaceuticals
$1.99 /

+ (+0.00%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$80.54 /

+ (+0.00%)

05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GLMD Galmed
$5.80 /

+ (+0.00%)

ENTA Enanta
$55.12 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

Over a week ago
Options
Largest borrow rate increases among liquid names » 08:45
05/15/20
05/15
08:45
05/15/20
08:45
AAL

American Airlines

$9.10 /

+ (+0.00%)

, IVR

Invesco Mortgage

$2.70 /

+0.105 (+4.05%)

, SFIX

Stitch Fix

$19.45 /

+0.91 (+4.91%)

, MARK

Remark Holdings

$1.39 /

-0.34 (-19.65%)

, VHC

VirnetX

$6.03 /

-0.015 (-0.25%)

, HOME

At Home Group

$2.70 /

+0.13 (+5.06%)

, CAR

Avis Budget

$11.87 /

+1.12 (+10.42%)

, ALT

Altimmune

$4.48 /

+0.35 (+8.47%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: American Airlines (AAL) 40.32% +9.15, Invesco Mortgage (IVR) 2.01% +0.96, Stitch Fix (SFIX) 18.33% +0.80, Remark Media (MARK) 44.72% +0.68, VirnetX (VHC) 4.40% +0.56, At Home Group (HOME) 0.81% +0.31, Avis Budget (CAR) 3.90% +0.29, iShares Goldman Sachs Software Index Fund (IGV) 1.69% +0.26, ProShares VIX Short Term Futures (VIXY) 3.74% +0.24, and Altimmune (ALT) 54.71% +0.16.

ShowHide Related Items >><<
VHC VirnetX
$6.03 /

-0.015 (-0.25%)

SFIX Stitch Fix
$19.45 /

+0.91 (+4.91%)

MARK Remark Holdings
$1.39 /

-0.34 (-19.65%)

IVR Invesco Mortgage
$2.70 /

+0.105 (+4.05%)

HOME At Home Group
$2.70 /

+0.13 (+5.06%)

CAR Avis Budget
$11.87 /

+1.12 (+10.42%)

ALT Altimmune
$4.48 /

+0.35 (+8.47%)

AAL American Airlines
$9.10 /

+ (+0.00%)

AAL American Airlines
$9.10 /

+ (+0.00%)

05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
American Airlines downgraded to Underweight from Equal Weight at Barclays
05/01/20 Evercore ISI
American Airlines price target lowered to $1 from $10 at Evercore ISI
04/27/20 Citi
American Airlines price target lowered to $10 from $13 at Citi
IVR Invesco Mortgage
$2.70 /

+0.105 (+4.05%)

04/08/20 JonesTrading
Invesco Mortgage downgraded to Hold from Buy at JonesTrading
SFIX Stitch Fix
$19.45 /

+0.91 (+4.91%)

04/21/20 SunTrust
Stitch Fix price target lowered to $22 from $27 at SunTrust
04/09/20 KeyBanc
Stitch Fix price target lowered to $18 from $26 at KeyBanc
04/09/20 Nomura Instinet
Nomura sees 'several silver linings' in Stitch Fix pulling guidance
04/09/20 Piper Sandler
Stitch Fix price target lowered to $11 from $15 at Piper Sandler
MARK Remark Holdings
$1.39 /

-0.34 (-19.65%)

07/15/19 Roth Capital
Sharecare liquidity event would help capitalize Remark AI business, says Roth Capital
VHC VirnetX
$6.03 /

-0.015 (-0.25%)

HOME At Home Group
$2.70 /

+0.13 (+5.06%)

03/25/20 Guggenheim
Guggenheim cuts At Home Group to Neutral on 'unprecedented demand uncertainty'
03/25/20 Guggenheim
At Home Group downgraded to Neutral from Buy at Guggenheim
01/21/20 KeyBanc
At Home Group downgraded to Sector Weight from Overweight at KeyBanc
12/06/19 Jefferies
At Home Group downgraded to Hold at Jefferies until visibility improves
CAR Avis Budget
$11.87 /

+1.12 (+10.42%)

05/06/20 Deutsche Bank
Avis Budget price target lowered to $16 from $18 at Deutsche Bank
05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/23/20 JPMorgan
JPMorgan downgrades Avis Budget to Neutral on travel fall off, used car prices
04/23/20 JPMorgan
Avis Budget downgraded to Neutral from Overweight at JPMorgan
ALT Altimmune
$4.48 /

+0.35 (+8.47%)

05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
SFIX Stitch Fix
$19.45 /

+0.91 (+4.91%)

IVR Invesco Mortgage
$2.70 /

+0.105 (+4.05%)

HOME At Home Group
$2.70 /

+0.13 (+5.06%)

CAR Avis Budget
$11.87 /

+1.12 (+10.42%)

ALT Altimmune
$4.48 /

+0.35 (+8.47%)

AAL American Airlines
$9.10 /

+ (+0.00%)

VHC VirnetX
$6.03 /

-0.015 (-0.25%)

CAR Avis Budget
$11.87 /

+1.12 (+10.42%)

AAL American Airlines
$9.10 /

+ (+0.00%)

VHC VirnetX
$6.03 /

-0.015 (-0.25%)

SFIX Stitch Fix
$19.45 /

+0.91 (+4.91%)

MARK Remark Holdings
$1.39 /

-0.34 (-19.65%)

IVR Invesco Mortgage
$2.70 /

+0.105 (+4.05%)

HOME At Home Group
$2.70 /

+0.13 (+5.06%)

CAR Avis Budget
$11.87 /

+1.12 (+10.42%)

ALT Altimmune
$4.48 /

+0.35 (+8.47%)

AAL American Airlines
$9.10 /

+ (+0.00%)

VHC VirnetX
$6.03 /

-0.015 (-0.25%)

SFIX Stitch Fix
$19.45 /

+0.91 (+4.91%)

IVR Invesco Mortgage
$2.70 /

+0.105 (+4.05%)

HOME At Home Group
$2.70 /

+0.13 (+5.06%)

CAR Avis Budget
$11.87 /

+1.12 (+10.42%)

ALT Altimmune
$4.48 /

+0.35 (+8.47%)

AAL American Airlines
$9.10 /

+ (+0.00%)

Hot Stocks
Altimmune appoints Diane Jorkasky to board of directors » 07:24
05/12/20
05/12
07:24
05/12/20
07:24
ALT

Altimmune

$3.17 /

+0.07 (+2.26%)

Altimmune announced the…

Altimmune announced the appointment of Diane Jorkasky, M.D. to its Board of Directors. With Dr. Jorkasky's appointment, the size of the board increased to eight members. Prior to her current roles, she was Chief Medical Officer and Head of Development of Complexa Inc., Chief Medical Officer of Endo Pharmaceuticals, and Chief Development and Medical Officer of Aileron Therapeutics.

ShowHide Related Items >><<
ALT Altimmune
$3.17 /

+0.07 (+2.26%)

ALT Altimmune
$3.17 /

+0.07 (+2.26%)

05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
ALT Altimmune
$3.17 /

+0.07 (+2.26%)

ALT Altimmune
$3.17 /

+0.07 (+2.26%)

ALT Altimmune
$3.17 /

+0.07 (+2.26%)

On The Fly
Novo Nordisk slips as analysts discuss NASH data, read-through to peers » 14:46
05/06/20
05/06
14:46
05/06/20
14:46
NVO

Novo Nordisk

$62.47 /

-0.81 (-1.28%)

, ICPT

Intercept

$89.74 /

+9.16 (+11.37%)

, NGM

NGM Biopharmaceuticals

$19.99 /

+2.06 (+11.49%)

, GNFT

Genfit

$21.09 /

-0.85 (-3.87%)

, ALT

Altimmune

$3.02 /

-0.11 (-3.51%)

, AKRO

Akero Therapeutics

$20.95 /

+0.27 (+1.31%)

, BMY

Bristol-Myers

$61.48 /

+0.13 (+0.21%)

, MDGL

Madrigal Pharmaceuticals

$88.54 /

-0.01 (-0.01%)

, VKTX

Viking Therapeutics

$6.64 /

-0.05 (-0.75%)

In conjunction with the…

Open Full Text

ShowHide Related Items >><<
NVO Novo Nordisk
$62.47 /

-0.81 (-1.28%)

05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
05/04/20
Fly Intel: Top five analyst initiations
ICPT Intercept
$89.74 /

+9.16 (+11.37%)

04/02/20 Chardan
Intercept initiated with a Buy at Chardan
03/19/20 JMP Securities
JMP Securities says report on Intercept's OCA 'favorable'
NGM NGM Biopharmaceuticals
$19.99 /

+2.06 (+11.49%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
GNFT Genfit
$21.09 /

-0.85 (-3.87%)

04/09/20 H.C. Wainwright
Genfit price target lowered to $46 from $58 at H.C. Wainwright
01/23/20 B. Riley FBR
Genfit selloff on data speculation unwarranted, says B. Riley FBR
ALT Altimmune
$3.02 /

-0.11 (-3.51%)

04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
AKRO Akero Therapeutics
$20.95 /

+0.27 (+1.31%)

03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
BMY Bristol-Myers
$61.48 /

+0.13 (+0.21%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
04/02/20
Fly Intel: Top five analyst upgrades
04/02/20 Morgan Stanley
Bristol-Myers upgraded to Overweight after pullback at Morgan Stanley
04/02/20 Morgan Stanley
Bristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
MDGL Madrigal Pharmaceuticals
$88.54 /

-0.01 (-0.01%)

05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
03/05/20 Citi
Madrigal Pharmaceuticals price target lowered to $155 from $166 at Citi
VKTX Viking Therapeutics
$6.64 /

-0.05 (-0.75%)

05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley FBR
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
05/01/20 BTIG
Viking Therapeutics initiated with a Buy at BTIG
02/27/20 H.C. Wainwright
Viking Therapeutics price target lowered to $18 from $31 at H.C. Wainwright
Recommendations
Novo data 'sets up the runway' for Altimmune, says Roth Capital » 13:23
05/06/20
05/06
13:23
05/06/20
13:23
ALT

Altimmune

$3.05 /

-0.08 (-2.56%)

, NVO

Novo Nordisk

$62.62 /

-0.66 (-1.04%)

With release of Novo…

With release of Novo Nordisk's (NVO) Phase 2b nonalcoholic steatohepatitis data for semaglutide this morning, all eyes are on what this means for other compounds utilizing GLP-1 and the broader NASH space, Roth Capital analyst Yasmeen Rahimi tells investors in a research note. The analyst sees the semaglutide readout as "strong validation" of GLP-1 agonism as a NASH mechanism of action. Further, questions left unanswered from today's dataset are "exactly the strategic areas" where Altimmune's dual GLP-1:glucagon agonist, ALT-801, can demonstrate substantial improvement on sole GLP-1 drugs, Rahimi tells investors in a research note. Today's GLP-1 data "sets up the runway for ALT-801 to take off in the near-term," says the analyst. Rahimi keeps a Buy rating on Altimmune with a $13 price target. The stock in afternoon trading is down 11c to $3.04.

ShowHide Related Items >><<
ALT Altimmune
$3.05 /

-0.08 (-2.56%)

04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
02/24/20 Roth Capital
Altimmune resumed with a Buy at Roth Capital
NVO Novo Nordisk
$62.62 /

-0.66 (-1.04%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
05/04/20
Fly Intel: Top five analyst initiations
05/04/20 Cowen
Novo Nordisk initiated with a Market Perform at Cowen
03/23/20 UBS
Novo Nordisk upgraded to Buy from Neutral at UBS
Conference/Events
Roth Capital biotech analyst to hold an analyst/industry conference call » 11:25
05/01/20
05/01
11:25
05/01/20
11:25
AKRO

Akero Therapeutics

$20.23 /

-0.26 (-1.27%)

, ALT

Altimmune

$2.92 /

-0.11 (-3.63%)

, ENTA

Enanta

$47.58 /

+1.2 (+2.59%)

, GLMD

Galmed

$4.25 /

-0.21 (-4.71%)

, GNFT

Genfit

$21.00 /

-0.6 (-2.78%)

, HEPA

Hepion Pharmaceuticals

$1.78 /

-0.1 (-5.32%)

, ICPT

Intercept

$77.05 /

-4.71 (-5.76%)

, MDGL

Madrigal Pharmaceuticals

$82.18 /

-1.5 (-1.79%)

, NGM

NGM Biopharmaceuticals

$16.50 /

-1.74 (-9.54%)

Biotechnology Analyst…

Biotechnology Analyst Rahimi, along with Dr. Juan Frias, discuss the effectiveness of GLP-1 agonists in improving liver histology in patients with NASH on an Analyst/Industry conference call to be held on May 1 at 12 pm.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$20.23 /

-0.26 (-1.27%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$2.92 /

-0.11 (-3.63%)

04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
02/24/20 Roth Capital
Altimmune resumed with a Buy at Roth Capital
ENTA Enanta
$47.58 /

+1.2 (+2.59%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$4.25 /

-0.21 (-4.71%)

02/04/20 Craig-Hallum
Galmed initiated with a Buy at Craig-Hallum
01/30/20 Cantor Fitzgerald
Cantor sees valuation disconnect for Galmed. assumes with Overweight
01/30/20 Cantor Fitzgerald
Galmed assumed with an Overweight at Cantor Fitzgerald
12/02/19 Canaccord
Galmed initiated with a Buy at Canaccord
GNFT Genfit
$21.00 /

-0.6 (-2.78%)

04/09/20 H.C. Wainwright
Genfit price target lowered to $46 from $58 at H.C. Wainwright
01/23/20 B. Riley FBR
Genfit selloff on data speculation unwarranted, says B. Riley FBR
12/19/19 Roth Capital
Roth says Genfit 'unlocking the power' of non-invasive diagnosis of NASH
11/26/19 H.C. Wainwright
Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright
HEPA Hepion Pharmaceuticals
$1.78 /

-0.1 (-5.32%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$77.05 /

-4.71 (-5.76%)

04/02/20 Chardan
Intercept initiated with a Buy at Chardan
03/19/20 JMP Securities
JMP Securities says report on Intercept's OCA 'favorable'
03/05/20 BofA
Intercept reinstated with a Neutral at BofA
02/26/20 Cantor Fitzgerald
Intercept shares attractive after pullback, says Cantor Fitzgerald
MDGL Madrigal Pharmaceuticals
$82.18 /

-1.5 (-1.79%)

03/05/20 Citi
Madrigal Pharmaceuticals price target lowered to $155 from $166 at Citi
01/30/20
Fly Intel: Top five analyst initiations
01/30/20 Canaccord
Madrigal Pharmaceuticals initiated with a Buy at Canaccord
NGM NGM Biopharmaceuticals
$16.50 /

-1.74 (-9.54%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
02/26/20 B. Riley FBR
NGM Biopharmaceuticals price target raised to $30 from $24 at B. Riley FBR
Conference/Events
Roth Capital biotech analyst to hold an analyst/industry conference call » 04:55
05/01/20
05/01
04:55
05/01/20
04:55
AKRO

Akero Therapeutics

$20.49 /

-0.95 (-4.43%)

, ALT

Altimmune

$3.03 /

-0.02 (-0.66%)

, ENTA

Enanta

$46.38 /

-2.6 (-5.31%)

, GLMD

Galmed

$4.46 /

+0.01 (+0.22%)

, GNFT

Genfit

$21.60 /

+0.3 (+1.41%)

, HEPA

Hepion Pharmaceuticals

$1.88 /

+0.205 (+12.24%)

, ICPT

Intercept

$81.76 /

-2.16 (-2.57%)

, MDGL

Madrigal Pharmaceuticals

$83.68 /

-4.03 (-4.59%)

, NGM

NGM Biopharmaceuticals

$18.24 /

-0.06 (-0.33%)

Biotechnology Analyst…

Biotechnology Analyst Rahimi, along with Dr. Juan Frias, discuss the effectiveness of GLP-1 agonists in improving liver histology in patients with NASH on an Analyst/Industry conference call to be held on May 1 at 12 pm.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$20.49 /

-0.95 (-4.43%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$3.03 /

-0.02 (-0.66%)

04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
02/24/20 Roth Capital
Altimmune resumed with a Buy at Roth Capital
ENTA Enanta
$46.38 /

-2.6 (-5.31%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$4.46 /

+0.01 (+0.22%)

02/04/20 Craig-Hallum
Galmed initiated with a Buy at Craig-Hallum
01/30/20 Cantor Fitzgerald
Cantor sees valuation disconnect for Galmed. assumes with Overweight
01/30/20 Cantor Fitzgerald
Galmed assumed with an Overweight at Cantor Fitzgerald
12/02/19 Canaccord
Galmed initiated with a Buy at Canaccord
GNFT Genfit
$21.60 /

+0.3 (+1.41%)

04/09/20 H.C. Wainwright
Genfit price target lowered to $46 from $58 at H.C. Wainwright
01/23/20 B. Riley FBR
Genfit selloff on data speculation unwarranted, says B. Riley FBR
12/19/19 Roth Capital
Roth says Genfit 'unlocking the power' of non-invasive diagnosis of NASH
11/26/19 H.C. Wainwright
Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright
HEPA Hepion Pharmaceuticals
$1.88 /

+0.205 (+12.24%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$81.76 /

-2.16 (-2.57%)

04/02/20 Chardan
Intercept initiated with a Buy at Chardan
03/19/20 JMP Securities
JMP Securities says report on Intercept's OCA 'favorable'
03/05/20 BofA
Intercept reinstated with a Neutral at BofA
02/26/20 Cantor Fitzgerald
Intercept shares attractive after pullback, says Cantor Fitzgerald
MDGL Madrigal Pharmaceuticals
$83.68 /

-4.03 (-4.59%)

03/05/20 Citi
Madrigal Pharmaceuticals price target lowered to $155 from $166 at Citi
01/30/20
Fly Intel: Top five analyst initiations
01/30/20 Canaccord
Madrigal Pharmaceuticals initiated with a Buy at Canaccord
NGM NGM Biopharmaceuticals
$18.24 /

-0.06 (-0.33%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
02/26/20 B. Riley FBR
NGM Biopharmaceuticals price target raised to $30 from $24 at B. Riley FBR
Over a month ago
Conference/Events
Roth Capital biotech analyst to hold an analyst/industry conference call » 16:56
04/26/20
04/26
16:56
04/26/20
16:56
AKRO

Akero Therapeutics

$19.23 /

-0.12 (-0.62%)

, ALT

Altimmune

$3.18 /

+0.1 (+3.25%)

, ENTA

Enanta

$53.51 /

+1.05 (+2.00%)

, GLMD

Galmed

$4.51 /

+0.16 (+3.68%)

, GNFT

Genfit

$19.60 /

-0.16 (-0.81%)

, HEPA

Hepion Pharmaceuticals

$1.38 /

-0.14 (-9.21%)

, ICPT

Intercept

$83.45 /

+2.64 (+3.27%)

, MDGL

Madrigal Pharmaceuticals

$90.36 /

+5.26 (+6.18%)

, NGM

NGM Biopharmaceuticals

$17.60 /

+1.23 (+7.51%)

Biotechnology Analyst…

Biotechnology Analyst Rahimi, along with Dr. Juan Frias, discuss the effectiveness of GLP-1 agonists in improving liver histology in patients with NASH on an Analyst/Industry conference call to be held on May 1 at 12 pm.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$19.23 /

-0.12 (-0.62%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$3.18 /

+0.1 (+3.25%)

04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
02/24/20 Roth Capital
Altimmune resumed with a Buy at Roth Capital
ENTA Enanta
$53.51 /

+1.05 (+2.00%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$4.51 /

+0.16 (+3.68%)

02/04/20 Craig-Hallum
Galmed initiated with a Buy at Craig-Hallum
01/30/20 Cantor Fitzgerald
Cantor sees valuation disconnect for Galmed. assumes with Overweight
01/30/20 Cantor Fitzgerald
Galmed assumed with an Overweight at Cantor Fitzgerald
12/02/19 Canaccord
Galmed initiated with a Buy at Canaccord
GNFT Genfit
$19.60 /

-0.16 (-0.81%)

04/09/20 H.C. Wainwright
Genfit price target lowered to $46 from $58 at H.C. Wainwright
01/23/20 B. Riley FBR
Genfit selloff on data speculation unwarranted, says B. Riley FBR
12/19/19 Roth Capital
Roth says Genfit 'unlocking the power' of non-invasive diagnosis of NASH
11/26/19 H.C. Wainwright
Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright
HEPA Hepion Pharmaceuticals
$1.38 /

-0.14 (-9.21%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$83.45 /

+2.64 (+3.27%)

04/02/20 Chardan
Intercept initiated with a Buy at Chardan
03/19/20 JMP Securities
JMP Securities says report on Intercept's OCA 'favorable'
03/05/20 BofA
Intercept reinstated with a Neutral at BofA
02/26/20 Cantor Fitzgerald
Intercept shares attractive after pullback, says Cantor Fitzgerald
MDGL Madrigal Pharmaceuticals
$90.36 /

+5.26 (+6.18%)

03/05/20 Citi
Madrigal Pharmaceuticals price target lowered to $155 from $166 at Citi
01/30/20
Fly Intel: Top five analyst initiations
01/30/20 Canaccord
Madrigal Pharmaceuticals initiated with a Buy at Canaccord
NGM NGM Biopharmaceuticals
$17.60 /

+1.23 (+7.51%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
02/26/20 B. Riley FBR
NGM Biopharmaceuticals price target raised to $30 from $24 at B. Riley FBR
Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 11:25
04/20/20
04/20
11:25
04/20/20
11:25
AKRO

Akero Therapeutics

$21.06 /

+0.355 (+1.71%)

, ALT

Altimmune

$3.33 /

+0.03 (+0.91%)

, ENTA

Enanta

$56.03 /

+1.14 (+2.08%)

, GLMD

Galmed

$5.17 /

+0.39 (+8.16%)

, GNFT

Genfit

$19.65 /

+1.93 (+10.89%)

, HEPA

Hepion Pharmaceuticals

$1.59 /

+0.08 (+5.32%)

, ICPT

Intercept

$85.10 /

+3.79 (+4.66%)

, MDGL

Madrigal Pharmaceuticals

$89.82 /

+7.49 (+9.10%)

, NGM

NGM Biopharmaceuticals

$15.83 /

+0.48 (+3.13%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Manal Abdelmalek, discusses Non-Alcoholic SteatoHepatitis (NASH) and how COVID-19 impacts trial timelines on an Analyst/Industry conference call to be held on April 20 at 12 pm.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$21.06 /

+0.355 (+1.71%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$3.33 /

+0.03 (+0.91%)

04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
02/24/20 Roth Capital
Altimmune resumed with a Buy at Roth Capital
ENTA Enanta
$56.03 /

+1.14 (+2.08%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$5.17 /

+0.39 (+8.16%)

02/04/20 Craig-Hallum
Galmed initiated with a Buy at Craig-Hallum
01/30/20 Cantor Fitzgerald
Cantor sees valuation disconnect for Galmed. assumes with Overweight
01/30/20 Cantor Fitzgerald
Galmed assumed with an Overweight at Cantor Fitzgerald
12/02/19 Canaccord
Galmed initiated with a Buy at Canaccord
GNFT Genfit
$19.65 /

+1.93 (+10.89%)

04/09/20 H.C. Wainwright
Genfit price target lowered to $46 from $58 at H.C. Wainwright
01/23/20 B. Riley FBR
Genfit selloff on data speculation unwarranted, says B. Riley FBR
12/19/19 Roth Capital
Roth says Genfit 'unlocking the power' of non-invasive diagnosis of NASH
11/26/19 H.C. Wainwright
Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright
HEPA Hepion Pharmaceuticals
$1.59 /

+0.08 (+5.32%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$85.10 /

+3.79 (+4.66%)

04/02/20 Chardan
Intercept initiated with a Buy at Chardan
03/19/20 JMP Securities
JMP Securities says report on Intercept's OCA 'favorable'
03/05/20 BofA
Intercept reinstated with a Neutral at BofA
02/26/20 Cantor Fitzgerald
Intercept shares attractive after pullback, says Cantor Fitzgerald
MDGL Madrigal Pharmaceuticals
$89.82 /

+7.49 (+9.10%)

03/05/20 Citi
Madrigal Pharmaceuticals price target lowered to $155 from $166 at Citi
01/30/20
Fly Intel: Top five analyst initiations
01/30/20 Canaccord
Madrigal Pharmaceuticals initiated with a Buy at Canaccord
NGM NGM Biopharmaceuticals
$15.83 /

+0.48 (+3.13%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
02/26/20 B. Riley FBR
NGM Biopharmaceuticals price target raised to $30 from $24 at B. Riley FBR

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.